Adult hepatocellular carcinoma

Summary

Adult hepatocellular carcinoma (MONDO:0016216) is a cancer and 158 clinical trials. Top therapeutic interventions include sorafenib, lapatinib, and tivozanib. A subtype of hepatocellular carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Clinical trials: 158

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	3.22	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	adult hepatocellular carcinoma
Mondo ID	MONDO:0016216
Orphanet	210159
DOID	DOID:0070328
NCIT	C7956
UMLS	C0279607
MedGen	124633
GARD	0006608
Is cancer (heuristic)	yes

Also known as: adult HCC · adult hepatocellular carcinoma · adult hepatoma · adult primary carcinoma of liver cell · adult primary carcinoma of the liver cell · adult primary hepatocellular carcinoma · adult primary hepatoma · adult primary liver cell carcinoma · hepatocellular cancer · hepatocellular carcinoma of adults

Data availability: 433 cell lines.

Disease family

This is a subtype of hepatocellular carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › hepatocellular carcinoma › adult hepatocellular carcinoma

Related subtypes (7): hepatocellular clear cell carcinoma, aflatoxin-related hepatocellular carcinoma, sclerosing hepatic carcinoma, fibrolamellar hepatocellular carcinoma, liver diffuse large B-cell lymphoma, pediatric hepatocellular carcinoma, hepatoblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 158.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	55
Not specified	51
PHASE1	28
PHASE1/PHASE2	14
PHASE3	4
PHASE4	3
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05185505	PHASE4	RECRUITING	Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT01849588	PHASE4	TERMINATED	HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
NCT03151213	PHASE4	COMPLETED	Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver
NCT01015833	PHASE3	COMPLETED	Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT01405573	PHASE3	TERMINATED	Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
NCT01655641	PHASE2/PHASE3	UNKNOWN	Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery
NCT01730937	PHASE3	COMPLETED	Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
NCT01829035	PHASE3	COMPLETED	A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
NCT03937830	PHASE2	ACTIVE_NOT_RECRUITING	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
NCT04912765	PHASE2	RECRUITING	Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
NCT05438420	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
NCT05451043	PHASE2	RECRUITING	Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
NCT05992220	PHASE2	RECRUITING	Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
NCT06239194	PHASE1/PHASE2	RECRUITING	Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06362369	PHASE1/PHASE2	RECRUITING	A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06935175	PHASE2	NOT_YET_RECRUITING	A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
NCT07227012	PHASE1/PHASE2	RECRUITING	Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT00006016	PHASE2	COMPLETED	Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
NCT00023946	PHASE2	TERMINATED	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
NCT00033462	PHASE2	COMPLETED	Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
NCT00047333	PHASE2	TERMINATED	Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
NCT00052364	PHASE2	COMPLETED	Oxaliplatin in Treating Patients With Liver Cancer
NCT00055692	PHASE2	COMPLETED	Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
NCT00071994	PHASE2	COMPLETED	Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
NCT00077441	PHASE2	COMPLETED	Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
NCT00083226	PHASE2	COMPLETED	Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
NCT00101036	PHASE2	COMPLETED	Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
NCT00107536	PHASE2	COMPLETED	Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
NCT00238394	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00321594	PHASE1/PHASE2	COMPLETED	Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
NCT00365391	PHASE2	COMPLETED	Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
NCT00427973	PHASE2	TERMINATED	AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
NCT00459108	PHASE2	TERMINATED	Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
NCT00604721	PHASE2	COMPLETED	Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00639509	PHASE2	COMPLETED	IMC-A12 in Treating Patients With Advanced Liver Cancer
NCT00787787	PHASE2	TERMINATED	Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
NCT00813293	PHASE2	COMPLETED	Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
NCT00878215	PHASE2	TERMINATED	Clinical Application of Image-Guided Liver Surgery
NCT01010126	PHASE2	COMPLETED	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
NCT01194206	PHASE2	WITHDRAWN	Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SORAFENIB	4	23
LAPATINIB	4	6
TIVOZANIB	4	4
CHLOROTRIANISENE	4	3
ERLOTINIB HYDROCHLORIDE	4	3
DASATINIB ANHYDROUS	4	2
ATEZOLIZUMAB	4	1
BELINOSTAT	4	1
BEVACIZUMAB	4	1
FERUMOXYTOL	4	1
GADOXETATE DISODIUM	4	1
GEFITINIB	4	1
IXABEPILONE	4	1
PASIREOTIDE	4	1
PREGABALIN	4	1
RAMUCIRUMAB	4	1
SELUMETINIB	4	1
SUNITINIB MALATE	4	1
TEGAFUR	4	1
TEMSIROLIMUS	4	1
TRAMETINIB	4	1
CEDIRANIB MALEATE	3	2
CAROTUXIMAB	3	1
NISEVOKITUG	3	1
SASANLIMAB	3	1
SPARTALIZUMAB	3	1
CIXUTUMUMAB	2	2
ALINTEGIMOD	2	1
C-188-9	2	1
CARMOFUR	2	1